Table 2 Anti-proliferative activity against six kinds of breast cancer cells by all compounds.
From: Identification of New Shikonin Derivatives as Antitumor Agents Targeting STAT3 SH2 Domain
Compound | IC50 (μM) | |||||
|---|---|---|---|---|---|---|
MCF-7 | BT-474 | SKBR-3 | MDA-MB-436 | MDA-MB-231 | MDA-MB-468 | |
PMM-158 | 12.1 ± 0.42 | 15.6 ± 1.03 | 11.5 ± 0.74 | 10.1 ± 0.92 | 9.17 ± 0.99 | 10.6 ± 0.65 |
PMM-159 | 9.22 ± 0.13 | 10.8 ± 0.94 | 8.95 ± 0.69 | 8.49 ± 0.78 | 7.24 ± 0.82 | 8.23 ± 1.27 |
PMM-160 | 15.3 ± 0.52 | 18.3 ± 1.24 | 10.5 ± 0.88 | 11.8 ± 0.86 | 9.66 ± 1.21 | 12.4 ± 0.52 |
PMM-161 | 9.81 ± 0.49 | 11.1 ± 1.12 | 9.29 ± 0.66 | 9.55 ± 0.83 | 8.58 ± 0.53 | 8.97 ± 1.05 |
PMM-162 | 9.01 ± 0.92 | 9.54 ± 0.91 | 8.03 ± 0.83 | 7.28 ± 0.77 | 6.14 ± 1.05 | 6.85 ± 0.92 |
PMM-163 | 8.69 ± 0.83 | 9.27 ± 0.86 | 7.56 ± 0.72 | 7.09 ± 0.63 | 6.04 ± 0.59 | 7.83 ± 0.55 |
PMM-164 | 5.71 ± 0.52 | 7.09 ± 0.65 | 4.49 ± 0.58 | 4.41 ± 0.55 | 3.76 ± 1.02 | 3.94 ± 0.73 |
PMM-165 | 9.38 ± 0.66 | 9.22 ± 0.98 | 6.23 ± 0.73 | 5.97 ± 0.67 | 5.47 ± 1.01 | 6.58 ± 0.15 |
PMM-166 | 6.41 ± 0.75 | 6.91 ± 0.73 | 4.87 ± 0.58 | 4.66 ± 0.59 | 3.64 ± 0.91 | 4.07 ± 0.66 |
PMM-167 | 15.3 ± 0.61 | 13.7 ± 0.92 | 9.76 ± 0.95 | 10.6 ± 0.82 | 9.01 ± 0.56 | 12.2 ± 0.42 |
PMM-168 | 9.27 ± 1.12 | 10.6 ± 0.81 | 8.16 ± 0.71 | 7.87 ± 0.91 | 6.09 ± 1.04 | 8.42 ± 0.86 |
PMM-169 | 8.12 ± 0.98 | 8.36 ± 0.97 | 6.95 ± 0.82 | 7.36 ± 0.87 | 5.33 ± 0.77 | 7.22 ± 1.11 |
PMM-170 | 9.73 ± 1.03 | 12.7 ± 1.06 | 8.27 ± 0.69 | 6.88 ± 0.73 | 4.31 ± 0.65 | 8.44 ± 0.78 |
PMM-171 | 8.71 ± 0.67 | 8.59 ± 0.78 | 5.89 ± 0.64 | 6.49 ± 0.68 | 3.14 ± 1.02 | 6.95 ± 0.46 |
PMM-172 | 4.87 ± 0.55 | 5.26 ± 0.66 | 3.14 ± 0.46 | 3.07 ± 0.47 | 1.98 ± 0.49 | 3.24 ± 0.27 |
PMM-173 | 5.58 ± 0.83 | 6.03 ± 0.71 | 3.59 ± 0.49 | 4.06 ± 0.53 | 2.59 ± 0.19 | 3.76 ± 0.88 |
Shikonin | 4.57 ± 0.69 | 5.74 ± 0.66 | 3.75 ± 0.52 | 3.28 ± 0.41 | 2.88 ± 0.25 | 3.61 ± 0.34 |
Stattic | 5.85 ± 0.72 | 5.11 ± 0.57 | 3.39 ± 0.56 | 3.76 ± 0.50 | 3.18 ± 0.33 | 3.54 ± 0.42 |
